New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
09:03 EDTBAXBaxter presents data from AHEAD study
Baxter International presented clinical data on Baxter’s leading recombinant factor VIII treatment, including interim data from the first year of observation from the AHEAD study, a four-year outcomes registry of hemophilia A patients treated with ADVATE. These data were presented during the European Association for Haemophilia and Allied Disorders meeting in Brussels, Belgium. These real-world data, which support the clinical experience of prophylaxis treatment with ADVATE, found that the majority of patients (55.3%) on prophylaxis had fewer than two bleeding episodes per year, with a median annual bleed rate of 1.1. Of these patients, 51 percent experienced no bleeds during one year of treatment.
News For BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
07:42 EDTBAXBaxter still undervalued heading into split, says Leerink
Leerink its sum-of-the-parts analysis indicates Baxter shares remain undervalued heading into the company's split. The firm reiterates an Outperform rating on the name with a slightly reduced price target of $82.
February 23, 2015
09:08 EDTBAXBaxter announces Illinois headquarters for biopharmaceutical spin-off
Subscribe for More Information
February 20, 2015
07:08 EDTBAXAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
18:25 EDTBAXPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use